Stifel Reiterates Buy on ClearPoint Neuro, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Mathew Blackman has reiterated a Buy rating on ClearPoint Neuro (NASDAQ:CLPT) and increased the price target from $8 to $9.

March 13, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst Mathew Blackman reiterated a Buy rating on ClearPoint Neuro and raised the price target from $8 to $9.
The reiteration of a Buy rating combined with an increased price target typically signals a positive outlook on the company's future performance, potentially leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100